1	Development of a non-infectious control for viral hemorrhagic fever PCR assays
2	
3	Matthew A Knox <sup>*1</sup> , Collette Bromhead <sup>2</sup> , David TS Hayman <sup>1</sup>
4	
5	1. Massey University, School of Veterinary Science, Palmerston North, Manawatu-
6	Wanganui, New Zealand
7	2. Massey University, School of Health Sciences, Wellington, New Zealand
8	
9	* corresponding author M.Knox@massey.ac.nz
10	
11	Abstract
12	Assay validation is an essential component of disease surveillance but can be problematic in
13	low resource settings where access to positive control material is limited and a safety risk for
14	handlers. Here we describe techniques for validating the PCR based detection of Crimean-
15	Congo hemorrhagic fever orthonairovirus, Ebola virus, Lassa virus, Marburg virus and Rift
16	Valley Fever phlebovirus. We designed non-infectious synthetic DNA oligonucleotide
17	sequences incorporating primer binding sites suitable for multiple assays, and a T7 promotor
18	site which was used to transcribe the sequence. Transcribed RNA was used as template in a
19	dilution series, extracted and amplified with RT-PCR and RT-qPCR to demonstrate
20	successful recovery and determine limits of detection in a range of laboratory settings. Our
21	results are adaptable to any assay requiring validation of nucleic acid extraction and/or
22	amplification, particularly where sourcing reliable, safe material for positive controls is
23	infeasible.
24	

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 26 **Author Summary**

27

The majority of zoonoses originate in wildlife and tend to emerge from biodiverse regions in 28 29 low to middle income countries, frequently among deprived populations of at-risk people 30 with a lack of access to diagnostic capacity or surveillance. Diseases such as Crimean-Congo 31 Hemorrhagic Fever, Rift Valley Fever, Ebola Virus Disease, Marburg Virus Disease and Lassa Fever are viral hemorrhagic fevers (VHFs) and among the most neglected and serious 32 33 threats to global public health. This threat is partly due to the severity of disease caused by 34 these pathogens, but also because their geographical distribution is close to human 35 populations with often limited access to medical or diagnostic laboratory services. In our 36 study we describe and validate techniques for PCR based detection of five VHF viruses using 37 a synthetic, multi-target non-infectious positive control. Our work has applications in assay 38 design and optimization, particularly where access to source material is problematic or 39 requires high level biosafety containment, as is the case with VHF viruses. This approach can 40 help learners train in techniques used in nucleic acid extraction, amplification, and 41 sequencing of VHF viruses, but can be used for any targets, with potential for multiplexing 42 from a single positive control.

43

#### 45 Introduction

46 Medical advances including to healthcare access and sanitation have reduced infectious 47 disease mortality and morbidity globally. However, infectious diseases remain a significant 48 burden to many of the most deprived people in the world, and emerging infectious diseases 49 (EIDs) are serious public health threats, as evidenced by the emergence of SARS-CoV-2 and 50 COVID-19 pandemic in 2019 (1). Most EIDs are zoonotic in origin, meaning they emerge 51 from an animal and cross the species barrier to infect humans. Factors that lead to EID 52 emergence include socioeconomic factors, land use change, and urban population growth (2-53 5). The majority of zoonoses (e.g.  $\sim$ 72% (3)) originate in wildlife and because of these processes they tend to emerge from biodiverse regions in low to middle income countries 54 55 (LMICs) and frequently among deprived populations of at-risk people with a lack of access to 56 diagnostic capacity or surveillance. The recent global emergence of monkeypox virus 57 highlights the diagnostic issue further (6); the virus that causes Mpox (monkeypox), an 58 endemic zoonosis in West and Central Africa, must have emerged locally, possibly in 59 Nigeria, and gone undetected until it was detected in Europe (6). 60 Diseases such as Crimean-Congo Hemorrhagic Fever (CCHF), Rift Valley Fever (RVF), 61 Ebola Virus Disease (EVD), Marburg Virus Disease (MVD) and Lassa Fever (LF) are viral 62 hemorrhagic fevers (VHFs) and among the most neglected and serious threats to global 63 public health. This is in part due to the severity of disease caused by these pathogens, but also 64 because their geographical distribution is close to human populations with often limited 65 access to medical or diagnostic laboratory services. The large West African EVD outbreak 66 was likely able to establish during the months after the first case because early cases were not 67 detected in areas poorly served by diagnostic services (7). There is therefore an urgent need to develop tools for surveillance and diagnosis for both people and wildlife hosts for the 68 69 VHFs (8).

70 Numerous diagnostic assays exist for the viral agents of these VHFs (9-14). However, there 71 are difficulties in training personnel, particularly for VHFs and pathogens that are both rare 72 and highly pathogenic (15-17). Developments in synthesizing nucleic acids, however, allow 73 the synthesis of non-infectious control material for safe handling, including in low resource 74 settings (18, 19). Here, we designed synthetic DNA oligonucleotide sequences incorporating 75 primer binding sites suitable for five VHF (CCHF, RVF, EVD, MVD, LF) causing viruses 76 including a T7 promotor site to transcribe the sequence to enable RNA synthesis and provide 77 positive control material for all laboratory steps from nucleic acid extraction to detection. We 78 tested the sensitivity of extraction using both RT-PCR and RT-qPCR. In addition, since 79 access to refrigeration and cold storage is often not possible in field settings, we assess the 80 stability of reagents for amplification after storage at ambient temperature over a one-week 81 time course.

82

#### 83 Methods

#### 84 VHF Control Vector

85 A 1,000 bp DNA fragment was designed by generating random nucleotide sequence and 86 embedding previously published primer binding sites (9-14) within the sequence at positions 87 designed to amplify the target amplicon size for each assay. The fragment contained primer 88 binding positions for the amplification of five negative strand RNA viral pathogens, 89 comprising three viruses from the order Bunyavirales: Crimean-Congo hemorrhagic fever 90 orthonairovirus (CCHFV, family Nairoviridae), Lassa virus (LV, Lassa mammarenavirus, 91 family Arenaviridae), and Rift Valley fever phlebovirus (RVFV, family Phenuiviridae), and 92 two viruses from the order Mononegavirales: Ebola virus (EV, Zaire ebolavirus, family 93 Filoviridae) and Marburg virus (MV, Marburg marburgvirus, family Filoviridae) (Figure 1, 94 Table 1).

0	5
)	$\mathcal{I}$

	C 5 6 6 6 A T C C T A 6 6 C A T T T
	LV (long) F
тетатеетт техоссовта с <mark>авсстватскае сасабое</mark> вее в сасасавата со сасавата со сасавата стототото са са сасавата со с	G C G C T T A G A T A G C T T A G T
LV (short) F	
<u>2016</u> то в стаста стаста стала стастела в тей салонало са сталона стасте стаста стаста стала стала сталона таст	TT 6 6 T 6 C C T 6 A 6 A C C A T C
EVF	LV (short) R
1,0 170 170 170 170 170 170 170 170 170 17	400 A T A C G G A T A T T T T A C A C
LV (short) R EV R	
4,0 4,0 4,0 4,0 4,0 4,0 4,0 4,0 4,0 4,0	TTAAACGAAAGTGTGTTT
NELE	
KVPV P 510 520 520 540 550 560 570 580	590 500
— салесалтайтавлавалат <sup>т</sup> лвлателвв <sup>6</sup> лллс <u>ввтелйлетлвлттетелввлетте</u> бтеевттетвйвтевлееллёлв	GGGAGTATTAAAAACTG
MVF	MV B
620 620 620 620 640 550 560 570 580	spo zpo
ATTCAGESTEAC SCANSCATTAGATACTTTTCTATCSCESCCTAGACTAAATAGCATCCAATATTAGTSGCTCATCAC	CTTTGTGCAGGACAGGGG
MV R	LV (long) R
- 797 - 790	TAGTAGCATCTGTCGGAC
LV (long) R RVFV K RVFV RVFV	890 900
– A G A G C C G C T T G G C A A T A <u>T C T C A A A A A A C C C T C C G A A A A A A C G A T G C T A G T C A Ó A G G G A T G C G É C A A C G G A G G Ó G G</u>	ACCTAAGÁGCCATGGGAŤ
CCHEV F	
513 513 513 513 513 513 514 514 514 514 514 514 514 514 514 514	5 A T C A G G G A G A G C T C T G A
CCHFV R	

97

96

- 98 Figure 1. Viral hemorrhagic fever synthetic insert with primer sequence locations. See text
- 99 and Table 1 for details.

#### Table 1. Primers and probes for RT-PCR and RT-qPCR 100

101

Virus*	Forward primer (5'-3')	Reverse primer (5'-3')	Size (bp)	Reference
CCHFV	TCTCAAAGAAACACGTGCC	CCTTTTTGAACTCTTCAAACC	122	Atkinson et al., 2012
EV	TGGGCTGAAAAYTGCTACAA TC	CTTTGTGMACATASCGGCAC	111	Gibb et al., 2001
LV (long)	ACCGGGGGATCCTAGGCATTT	ATGACMATGCCCCTKTCCTGC ACAAAGAAC	580	Olschläger et al., 2010
LV (Short RT- qPCR)	AGCCTGATCCCAGATGCCAC ACATCTAG	TGCTGTTGGAGCGGCTGATGGT CTCAG	197	He et al., 2009
MV	GGTCAAACTAGATTCTCAGG ACTTC	GTCACCCCTGAATCAGTTTTTT	80	Huang et al 2012
RVFV	ATGATGACATT GAAGGGA	ATGCTGGGAAGTGATGAG	298	Garcia et al., 2001
β-globin internal control	AGAATCCAGATGCTCAAGGC	AGGTTCCTTTGTTCCCTAAGT	72	C. Bromhead; this study

102 \*CCHFV: Crimean-Congo hemorrhagic fever orthonairovirus; EV: Ebola virus; LV: Lassa virus; MV:

103 Marburg virus, and: RVFV: Rift Valley Fever phlebovirus.

- 105 The synthesised product was manufactured by GeneScript and cloned using pET-20b(+)
- 106 vector, which includes a T7 promoter site (Figure 2). The resulting lyophilized plasmid DNA
- 107 was reconstituted in 20 µL sterile water. RNA copies of the fragment were generated from
- 108 plasmid DNA using the MAXIscript T7 In Vitro Transcription kit (Ambion) following the
- 109 manufacturer's instructions. Synthesized RNA was then quantified using Qubit<sup>™</sup> RNA HS
- 110 (High Sensitivity) Assay Kit and stored at -80°C until further analyses. We estimated the
- 111 copy number based on the calculation which can be found at
- 112 <u>http://www.scienceprimer.com/copy-number-calculator-for-realtime-pcr.</u>
- 113



114

115 **Figure 2.** pET-20b(+) vector including insert, which is the sequence in Figure 1.

116

117 RNA extraction and 1-step RT-PCR

118	To simulate the biological sample processing steps, the synthetic VHF control RNA (550 -
119	$5.5 x 10^{11}$ copies) was added to 1 mL sterile PBS and then passed through a sterile 0.45 $\mu m$
120	filter (Macherey-Nagel GmbH & Co. KG, Düren, Germany). We used 200 $\mu$ L of filtrate as
121	the input material for nucleic acid extraction using the High Pure Viral Nucleic Acid kit
122	(Roche, New Zealand) according to the manufacturer's procedure. Extracted RNA was
123	amplified by 1 step RT-PCR using each of the five VHF primer sets (Table 1) and assay-
124	specific cycling protocols (Table 2). Each 20 $\mu L$ reaction consisted of 0.25 $\mu M$ each primer,
125	1 pg-1µg of template RNA (VHF Control Vector, GeneScript USA), 1 x PCR buffer and 0.5
126	µL SuperScript <sup>™</sup> III RT/Platinum <sup>™</sup> Taq High Fidelity Enzyme Mix (Invitrogen). RT-PCR
127	products were separated by agarose gel electrophoresis and visualised under UV light where
128	bands of the expected size were identified and excised. DNA was eluted in 50 $\mu L$ buffer (10
129	mM Tris, pH 8.0) for 12–24 hours at 4°C and then sent for bi-directional Sanger sequencing
130	to the Massey Genome Service (Massey University, Palmerston North, New Zealand).
131	

132 **Table 2**. Cycling conditions for 1-step RT-PCR assays

Virus*	Amplification**			Cycles
CCHFV	95°C 10 s	55°C 30 s	68°C 30 s	45
EV	94°C 15 s	60°C 30 s	68°C 30 s	40
LV (Long)	95°C 20 s	55°C 20 s	68°C 60 s	45
MV	94°C 15 s	60°C 30 s	68°C 30 s	45
RVFV	95°C 15 s	55°C 30 s	68°C 30 s	45

<sup>\*</sup>CCHFV: *Crimean-Congo hemorrhagic fever orthonairovirus;* EV: Ebola virus; LV: Lassa
virus; MV: Marburg virus, and: RVFV: *Rift Valley Fever phlebovirus.* \*\*Note that all 1-step
RT-PCR assays started with a cDNA synthesis step at 55°C for 30 min followed by an initial
denaturation at 95°C for 2 min.

137

138 To test the sensitivity of the nucleic acid extraction and 1-step RT-PCR assays, we conducted

a dilution series with the synthesized RNA. Dilutions for extraction were prepared in PCR

140 grade water and ranged from 31.2 to  $3.12 \times 10^{-8}$  ng (copy numbers  $5.5 \times 10^{11}$  to 550) and

141 followed the same biological sample processing steps as above.

#### 142 **RT-qPCR** assay and reagent stability experiments

- 143 All RT-qPCR assays used Ultraplex 1-Step ToughMix (Quantabio) and Eva®Green 20x
- 144 (Biotium, both from DNature NZ Ltd) on a Roche LightCycler-96 instrument. We included
- 145 two additional primer sets for RT-qPCR assays: a shorter Lassa virus amplicon (14) and a
- 146 beta-globin internal cellularity control ( $\beta$ -globin) which we found could be duplexed with
- 147 each VHF assay. Cycling conditions were optimised by testing annealing temperature
- 148 gradients from 55°C to 60°C in duplicate for all seven assays under the following
- 149 thermocycler conditions: 50°C for 10 mins, 95°C for 3 mins, 55 cycles of 95°C for 5 s, 55-
- 150 60°C for 15 s, 72°C for 30 s, with fluorescence acquired during the extension step
- 151 (excitation/emission Eva green = 488/530 nm). See Table 3 for optimal run conditions for
- 152 each VHF. Primer concentrations were optimised by titration from 0.2 to 0.6  $\mu$ M in 0.05  $\mu$ M
- 153 increments using a dilution series from 5000 copies/ $\mu$ L to 0.5 copies/ $\mu$ L of the synthetic
- 154 control extracted as for test samples (High Pure Viral kit, Roche New Zealand). The dilution
- series was used to determine the limit of detection of each assay (see results, Table 3).
- 156 Optimal reagent conditions for each VHF+  $\beta$ -globin RT-qPCR assay, in a 10  $\mu$ L reaction,
- 157 consisted of 1 x Toughmix 1-step buffer, 1 x Eva green dye, 0.45  $\mu$ M each primer (VHF +  $\beta$ -
- 158 globin), synthetic RNA control (50-5000 copies/µL) and RNAse-free water.
- 159 To assess the performance of our assays under potential field conditions where refrigeration
- 160 may not be available, we tested the performance of RT-qPCR reagents Ultraplex 1-Step
- 161 ToughMix and Eva®Green 20x stored at room temperature (12-28°C) for up to 1 week
- 162 before use. Duplicate RT-qPCR tests for each VHF were performed at each of three
- 163 timepoints (24 hours, 72 hours and 168 hours, 7 days) using the room temperature reagents.

- 164 Synthesised RNA from the VHF Control Vector was used as the template at a concentration
- 165 of 1,600-2,500 copies/µL.
- 166
- 167 **Results**

### 168 Dilution series RNA extraction and RT-PCR

- 169 RT-PCR performance varied among the assays (Supplementary Table 1, Supplementary
- 170 Figure 1). The results of a dilution series of synthetic control from 5.5E+11 to 552 copies
- 171 showed all five assays could detect to a limit of  $\sim$ 5.5 million copies/µL by gel
- electrophoresis, while the LV and MV could reliably detect 5.5E+4 and gave visible weak
- 173 bands at ~550 copies/µL. Sequencing of excised amplified products confirmed that recovered
- 174 DNA matched target amplicons (data not shown).

#### 175 VHF RT-qPCR assay and time course experiment

- 176 The RT-qPCR assays underwent optimisation for annealing temperatures, primer
- 177 concentrations and high-resolution melt (HRM) analysis. The results for these parameters as
- 178 well as the limits of detection for each RT-qPCR assay is shown in Table 3 and Figure 3.
- 179

180 **Table 3.** RT-qPCR VHF virus assay optimal experimental conditions and limits of detection.

Target*	Optimal annealing	TM of melting peaks	Limit of detection
	temperatures (°C)	(°C)	(copies/ $\mu$ L)
EV	55-61	82.5	50
RVFV	55-56	82.5	50
CCHFV	55-62	83	50
MV	55-61	78	50
LV-long	55-65	77	500
LV-short	55-58	81	50
β-globin	55-60	81	10

<sup>181 \*</sup>CCHFV: EV: Ebola virus; RVFV: *Rift Valley Fever phlebovirus; Crimean-Congo* 

182 *hemorrhagic fever orthonairovirus;* MV: Marburg virus, and: LV: Lassa virus.





Figure 3. High resolution melting peaks for EV and CCHFV (red), RVFV (turquoise), MV
(yellow) Short LV and β-globin (81°C purple), Long LV (77°C purple). Colours are grouped
by melting temperature (°C).

188 All assays could reliably detect 50 copies per  $\mu$ L except for the long LV assay which could 189 only detect down to 500 copies/uL reliably. The decreased efficiency of this assay indicated 190 it was not suitable for qPCR conversion. No change in primer concentration (0.45 mM) was 191 required for combining a VHF assay with the β-globin internal control (data not shown) and a 192 standard annealing temperature of 56°C was found to suit all assays. 193 We tested the performance of our VHF assays using RT-qPCR reagents stored at room 194 temperature (12-28°C), in the dark, for up to 1 week. Duplicate RT-qPCR tests for each VHF 195 were performed at each of three timepoints (24 hours, 72 hours and 7 days) using the 196 synthetic RNA control at a concentration of 1,600-2,500 copies/µL. 197 The average Cq values at 24 hours, 72 hours and 1 week all rose compared to time zero 198 (using ideal frozen reagents). The VHF virus RT-qPCR's biggest change was between 72 199 hours and 1 week for each VHF virus assay (Figure 4). The average Cq values were highest 200 for the LV assays, particularly the Long LV, indicating it was the most sensitive to reduced 201 efficiency reagents. By contrast, the MV assay maintained a low Cq across all three time 202 points. After 1 week, assay sensitivity for detecting 1000 copies/µL is significantly

- 203 compromised. Therefore 3 days (72 hours) at room temperature is the maximum
- 204 recommended storage time for Ultraplex 1-Step ToughMix (Quantabio) and Eva®Green 20x
- 205 (Biotium) for this testing purpose (See Supplementary Table 2 for the raw Cq data).
- 206



Figure 4. Room temperature stability of ToughMix and Eva Green for VHF virus RT-qPCR
assays.

210

### 211 Discussion

212 We have developed six assays for the most commonly occurring viral causes of VHF's using

both RT-PCR and RT-qPCR, incorporating an internal control for the latter, with the

214 possibility of multiplexing and using reagents stored at room temperature for up to 72 hours.

- 215 Our results demonstrate the applicability of synthetically designed nucleic acids for use as
- 216 molecular diagnostic assay controls in both RT-PCR and RT-qPCR methods. This work has
- 217 applications for assay design and optimization, particularly where access to source material is
- 218 problematic or requires high level biosafety containment, as is the case with VHF viruses.

219 This approach can help learners to train in techniques used in nucleic acid extraction,

amplification, and sequencing of VHF viruses, however, as well as providing ongoing

validation for the VHF viral assays we present, this approach can be used for any targets,

222 with potential for multiplexing from a single positive control.

223 Recent technological advances have greatly improved virus detection and diagnosis without

the need for multi-step RNA purification (20). New generation RT-qPCR reagents are more

225 robust to temperature storage above -20°C. These tests provide rapid, inexpensive, and

226 robust diagnoses where laboratory infrastructure is not available, and may replace current

technologies (i.e., RT-PCR assays) in some settings. However, there is an urgent need to

develop in-country tools for surveillance and diagnosis for both people and wildlife hosts for

the VHFs (8). Since our workflow requires only standard equipment, currently present in

230 most molecular biology labs it has applications for the design and validation of tests used in

surveillance of VHFs in countries where such work is most needed and for the time being

232 RT-PCR is likely to remain the most common method for many diagnostic laboratories.

233 Therefore, safe approaches to generate control material and to train staff are needed and our

work provides further evidence for the applicability of synthetic nucleic acids for use as assay

controls.

#### 236 Acknowledgements

237 This work was supported by funds from the World Organisation for Animal Health (Grant

238 3000034275; OIE Laboratory (or Collaborating Centre) Twinning Project: Enhancing

239 capacity for early detection of viral haemorrhagic fevers in Liberia through epidemiological

and laboratory training), Royal Society Te Apārangi Rutherford Discovery Fellowship (RDF-

241 MAU1701) and the Percival Carmine Chair in Epidemiology and Public Health (DTSH). We

242 wish to acknowledge the valuable contributions of WOAH staff, particularly Sophie Muset

and Mariana Marrana, and the Central Veterinary Laboratory team in Liberia.

## 244 Citations

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from 245 1. 246 patients with pneumonia in China, 2019. New England journal of medicine. 2020. 247 Jones BA, Grace D, Kock R, Alonso S, Rushton J, Said MY, et al. Zoonosis 2. 248 emergence linked to agricultural intensification and environmental change. Proceedings of 249 the National Academy of Sciences. 2013;110(21):8399-404. 250 Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, et al. Global 3. 251 trends in emerging infectious diseases. Nature. 2008;451(7181):990-3. 252 4. Rulli MC, Santini M, Hayman DT, D'Odorico P. The nexus between forest 253 fragmentation in Africa and Ebola virus disease outbreaks. Scientific reports. 2017;7:41613. 254 Stephens PR, Gottdenker N, Schatz AM, Schmidt JP, Drake JM. Characteristics of the 5. 255 100 largest modern zoonotic disease outbreaks. Philosophical Transactions of the Royal Society B: Biological Sciences. 2021;376(1837):20200535. 256 257 Gessain A, Nakoune E, Yazdanpanah Y. Monkeypox. New England Journal of 6. 258 Medicine. 2022;387(19):1783-93. 259 7. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba NF, et al. 260 Emergence of Zaire Ebola virus disease in Guinea. New England Journal of Medicine. 261 2014;371(15):1418-25. 262 8. Maudling R. How can One Health contribute to pandemic prevention? Looking at 263 Ebola through a One Health lens. CABI One Health. 2022(2022):ohcs20220004. Atkinson B, Chamberlain J, Logue CH, Cook N, Bruce C, Dowall SD, et al. 264 9. 265 Development of a real-time RT-PCR assay for the detection of Crimean-Congo hemorrhagic 266 fever virus. Vector Borne Zoonotic Dis. 2012;12(9):786-93. 267 10. Garcia S, Crance JM, Billecocq A, Peinnequin A, Jouan A, Bouloy M, et al. 268 Quantitative real-time PCR detection of Rift Valley fever virus and its application to 269 evaluation of antiviral compounds. J Clin Microbiol. 2001;39(12):4456-61. 270 Gibb TR, Norwood DA, Jr., Woollen N, Henchal EA. Development and evaluation of 11. 271 a fluorogenic 5' nuclease assav to detect and differentiate between Ebola virus subtypes Zaire 272 and Sudan. J Clin Microbiol. 2001;39(11):4125-30. Huang Y, Wei H, Wang Y, Shi Z, Raoul H, Yuan Z. Rapid detection of filoviruses by 273 12. 274 real-time TaqMan polymerase chain reaction assays. Virol Sin. 2012;27(5):273-7. 275 Olschläger S, Lelke M, Emmerich P, Panning M, Drosten C, Hass M, et al. Improved 13. 276 detection of Lassa virus by reverse transcription-PCR targeting the 5' region of S RNA. J Clin 277 Microbiol. 2010;48(6):2009-13. He J, Kraft AJ, Fan J, Van Dyke M, Wang L, Bose ME, et al. Simultaneous Detection 278 14. 279 of CDC Category "A" DNA and RNA Bioterrorism Agents by Use of Multiplex PCR & RT-280 PCR Enzyme Hybridization Assays. Viruses. 2009;1(3):441-59. 281 15. Worsley-Tonks KE, Bender JB, Deem SL, Ferguson AW, Fèvre EM, Martins DJ, et 282 al. Strengthening global health security by improving disease surveillance in remote rural 283 areas of low-income and middle-income countries. The Lancet Global Health. 284 2022;10(4):e579-e84. 16. 285 Molyneux D, Hallaj Z, Keusch GT, McManus DP, Ngowi H, Cleaveland S, et al. 286 Zoonoses and marginalised infectious diseases of poverty: where do we stand? Parasites & 287 vectors. 2011;4(1):1-6. Organization WH. WHO consultative meeting high/maximum containment (biosafety 288 17. 289 level 4) laboratories networking: venue: International Agency on Research on Cancer 290 (IARC), Lyon, France, 13-15 December 2017: meeting report. 2018.

- 18. Hayman DT, Banyard AC, Wakeley PR, Harkess G, Marston D, Wood JL, et al. A
- universal real-time assay for the detection of Lyssaviruses. Journal of virological methods.
  2011;177(1):87-93.
- 294 19. King DP, Reid SM, Hutchings GH, Grierson SS, Wilkinson PJ, Dixon LK, et al.
- 295 Development of a TaqMan® PCR assay with internal amplification control for the detection
- of African swine fever virus. Journal of Virological Methods. 2003;107(1):53-61.
- 297 20. Pollak NM, Olsson M, Marsh GA, Macdonald J, McMillan D. Evaluation of three
- rapid low-resource molecular tests for Nipah virus. Front Microbiol. 2022;13:1101914.

299

## 301 CreDit Author Contributions

302

# 303 **Matthew A Knox:** Investigation, Methodology, Formal Analysis, Visualization, Writing –

- 304 Original Draft Preparation.
- 305
- 306 Collette Bromhead: Investigation, Methodology, Validation, Formal Analysis, Writing -
- 307 Review & Editing.
- 308
- 309 David TS Hayman: Conceptualization, Funding Acquisition, Project Administration,
- 310 Writing Review & Editing.
- 311
- 312